REZOLUTE, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
REZOLUTE, INC. (RZLT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of -$400.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-09-24
- REZOLUTE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2026 was -$400.00K.
- REZOLUTE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was -$464.00K.
- REZOLUTE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was -$505.00K.
- REZOLUTE, INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was -$442.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2026-06-30 | -$400.00K 10-K · filed 2026-09-24 |
| 2025-06-30 | -$464.00K 10-K · filed 2026-09-24 |
| 2024-06-30 | -$505.00K 10-K · filed 2025-09-17 |
| 2023-06-30 | -$442.00K 10-K · filed 2024-09-19 |
| 2022-06-30 | -$527.00K 10-K · filed 2023-09-14 |
| 2021-06-30 | -$2.00K 10-K · filed 2022-09-15 |
| 2020-06-30 | -$12.00K 10-K · filed 2021-09-15 |
| 2019-06-30 | -$1.04M 10-K · filed 2020-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |